Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

CAR T-cell Therapy Articles

Axi-Cel Toxicity in LBCL May Be Alleviated With Earlier Steroid Use
Early steroid intervention has the potential to reduce the severity of adverse events associated with axicabtagene ciloleucel in patients with refractory large B-cell lymphoma, according to an analysis of the phase I/II ZUMA-1 trial.
FDA Grants Priority Review to Liso-Cel in Large B-Cell Lymphoma
The FDA has granted a priority review designation to a biologics license application for the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.
JNJ-4528 Boasts High Response Rate in Relapsed/Refractory Myeloma
Deepu Madduri, MD, discusses the results of the CARTITUDE-1 trial and the next phase of development with JNJ-4528.
CAR T-Cell Products Among Top Advances in Non-Hodgkin Lymphoma
Praveen Ramakrishnan, MD, spotlights some of the exciting data recently presented across the spectrum of non-Hodgkin lymphoma treatment.
CAR T-Cell Therapy Continues to Generate Positive Results in Hematologic Cancers
Ankit Kansagra, MD, discusses the evolving use of CAR T-cell therapy in multiple myeloma and lymphoma.
T-Cell Immunotherapy Pioneer Seeks New Direction for Solid Tumors
CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors.
Minimal residual disease has become an important investigational prognostic marker and risk stratification tool in acute lymphoblastic leukemia.
Exploration With Blinatumomab and CAR T-Cell Therapy Continues in ALL
Joseph Wynne, MD, discusses ongoing studies with blinatumomab and CAR T-cell therapy in acute lymphoblastic leukemia, as well as the importance of assessing minimal residual disease in this space.
Real-World Analysis Shows Cost-Reducing Benefit With CAR-T in Relapsed DLBCL
Karl M. Kilgore, PhD, discusses how results of real-world analysis may impact the utilization of CAR T-cell therapy for older patients with relapsed/refractory diffuse large B-cell lymphoma.
FDA Approval Sought for Liso-Cel in Large B-Cell Lymphoma
Bristol-Myers Squibb has submitted a biologics license application to the FDA seeking approval of the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.
Publication Bottom Border
Border Publication
x